Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Humana (HUM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Humana (HUM – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $330.00. The company’s shares closed last Wednesday at $221.49.
According to TipRanks.com, Archila is a 5-star analyst with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $287.42, which is a 29.6% upside from current levels. In a report issued on February 9, Morgan Stanley also maintained a Buy rating on the stock with a $250.00 price target.
See today’s best-performing stocks on TipRanks >>
Humana (HUM)
In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Humana, with a price target of $250.00. The company’s shares closed last Wednesday at $175.40.
According to TipRanks.com, Wiederhorn is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Moderate Buy with an average price target of $259.64, which is a 51.9% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $252.00 price target.
